GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $19.77 and traded as low as $19.32. GENMAB A/S/S shares last traded at $19.65, with a volume of 1,039,385 shares traded.
GENMAB A/S/S Stock Performance
The stock has a 50 day simple moving average of $19.77 and a two-hundred day simple moving average of $20.74.
About GENMAB A/S/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Featured Stories
- Five stocks we like better than GENMAB A/S/S
- What is a Stock Market Index and How Do You Use Them?
- Meta’s 5 Key Pillars for AI Growth—Zuckerberg’s Bold Vision
- How to Most Effectively Use the MarketBeat Earnings Screener
- Retail Investors Are Betting Big on Rocket Lab—Should You Too?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
